Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
June 10, 2022 03:04 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious...
Kronos Bio Announces Participation in Upcoming Investor Conferences
June 01, 2022 16:05 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious...
Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
May 17, 2022 07:00 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious...
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress
May 12, 2022 10:23 ET
|
Kronos Bio, Inc.
Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid leukemia (AML) Additional presentations detail...
Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
May 04, 2022 16:05 ET
|
Kronos Bio, Inc.
Preclinical data on CDK9 inhibitor KB-0742 presented at AACR add to evidence of potential activity in MYC-amplified and transcriptionally addicted tumors; company plans to announce RP2D and additional...
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR
April 08, 2022 13:07 ET
|
Kronos Bio, Inc.
Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue cancers, including sarcoma and...
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022
March 08, 2022 17:08 ET
|
Kronos Bio, Inc.
Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well as lymphomaPosters also feature data from...
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference
March 01, 2022 07:00 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other...
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
February 24, 2022 16:05 ET
|
Kronos Bio, Inc.
Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022 Lanraplenib...
Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development
February 01, 2022 16:05 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious...